Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 14, Pages 7889
Publisher
MDPI AG
Online
2022-07-18
DOI
10.3390/ijms23147889
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
- (2022) Zhi Qi et al. Nature Communications
- Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results From a Phase II Cohort
- (2022) D.S. Hong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
- (2022) Barbara Burtness et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
- (2022) Simon Eschweiler et al. NATURE
- Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer
- (2022) Lachlan McDowell et al. Frontiers in Oncology
- Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer
- (2021) Tien-Hua Chen et al. Journal of the Chinese Medical Association
- Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
- (2021) Shiwen Peng et al. mBio
- Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
- (2021) Christine H. Chung et al. Cancers
- Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
- (2021) Carlos Gomez‐Roca et al. CTS-Clinical and Translational Science
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
- (2021) Alan L. Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
- (2021) Assuntina G Sacco et al. LANCET ONCOLOGY
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
- (2021) Dan P Zandberg et al. Journal for ImmunoTherapy of Cancer
- DNA Methylation and HPV-Associated Head and Neck Cancer
- (2021) Takuya Nakagawa et al. Microorganisms
- Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- (2021) Grégoire Marret et al. INVESTIGATIONAL NEW DRUGS
- PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
- (2021) Matteo Caforio et al. Cancers
- Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
- (2021) Aini Hyytiäinen et al. Frontiers in Oncology
- Tisotumab Vedotin: First Approval
- (2021) Anthony Markham DRUGS
- Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers
- (2021) David E. Symer et al. GENOME RESEARCH
- Phase 1/2a, open‐label, multicenter study of RM ‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
- (2021) David M. Cognetti et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- 438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
- (2021) Christine Chung et al. Journal for ImmunoTherapy of Cancer
- Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers
- (2021) Jade Z. Zhou et al. Cancers
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma
- (2020) V. Sambandam et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.
- (2020) Faye M. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
- (2020) Alan Loh Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
- (2020) Kunal H. Bhatt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study
- (2020) Xu-Shan Sun et al. LANCET ONCOLOGY
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
- (2020) Hye Ryun Kim et al. BRITISH JOURNAL OF CANCER
- Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration
- (2020) Gioia Di Credico et al. BRITISH JOURNAL OF CANCER
- Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
- (2020) Olga Bednova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
- (2020) Cinzia Solinas et al. Translational Oncology
- Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics
- (2020) Junfang Lyu et al. Nature Communications
- The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
- (2020) Xin-wei Qiao et al. Frontiers in Immunology
- Personalized Cancer Vaccination in Head and Neck Cancer
- (2020) Hirofumi Shibata et al. CANCER SCIENCE
- Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
- (2020) Jamie V. Shiah et al. MOLECULAR CANCER THERAPEUTICS
- Head and neck squamous cell carcinoma
- (2020) Daniel E. Johnson et al. Nature Reviews Disease Primers
- NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma
- (2020) Pooja A. Shah et al. Cells
- PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
- (2019) Vaishnavi Sambandam et al. CLINICAL CANCER RESEARCH
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and Demographic Burden of HPV-associated Oropharyngeal Head and Neck Cancers in the United States
- (2019) Brandon A Mahal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Clinical update on head and neck cancer: molecular biology and ongoing challenges
- (2019) Elham Alsahafi et al. Cell Death & Disease
- Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
- (2019) Rodrigo Barbosa de Aguiar et al. Frontiers in Immunology
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
- (2019) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
- (2019) Panagiota Economopoulou et al. Frontiers in Oncology
- 1120PDBuparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial
- (2019) J Fayette et al. ANNALS OF ONCOLOGY
- 1210PPhase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
- (2019) C Le Tourneau et al. ANNALS OF ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
- (2019) Y Guo et al. ANNALS OF ONCOLOGY
- Epstein–Barr virus molecular epidemiology and variants identification in head and neck squamous cell carcinoma
- (2019) Mohammad Hadi Karbalaie Niya et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- (2019) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
- (2019) Franziska E. Marquard et al. BIOCHEMICAL PHARMACOLOGY
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- (2019) Cristina P. Rodriguez et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
- (2018) Yu-Lin Su et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
- (2018) Emanuele Giurisato et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Head and Neck Cancer by Vaccination
- (2018) Chuan Wang et al. Frontiers in Immunology
- Abstract 2977: PI3K/mTOR pathway inhibition induces Aurora B mediated cell death inNOTCH1mutant head and neck squamous (HNSCC) cells
- (2018) Vaishnavi Sambandam et al. CANCER RESEARCH
- A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
- (2018) Sophie Papa et al. JOURNAL OF CLINICAL ONCOLOGY
- Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers
- (2018) Mushfiq H. Shaikh et al. ORAL ONCOLOGY
- Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
- (2018) Steven F. Gameiro et al. OncoImmunology
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- 1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
- (2018) E E W Cohen et al. ANNALS OF ONCOLOGY
- Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
- (2018) Maura L. Gillison et al. GENOME RESEARCH
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
- (2018) Hisham Mehanna et al. LANCET
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene
- (2018) Xueqian Gong et al. Cancer Discovery
- Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
- (2018) Matthew G. Oser et al. Cancer Discovery
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
- (2017) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Denis Soulières et al. LANCET ONCOLOGY
- Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors
- (2017) David Martin et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Prevalence of high-risk human papillomavirus infection and cancer gene mutations in nonmalignant tonsils
- (2017) Taru Ilmarinen et al. ORAL ONCOLOGY
- Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
- (2017) Aviram Mizrachi et al. Nature Communications
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- Trial Watch: Adoptively transferred cells for anticancer immunotherapy
- (2017) Carole Fournier et al. OncoImmunology
- Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2017) Athanassios Argiris et al. Frontiers in Oncology
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
- (2016) Koos Koole et al. Molecular Diagnosis & Therapy
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
- (2016) Uddalak Bharadwaj et al. Oncotarget
- HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients
- (2016) Xavier Castellsagué et al. JNCI-Journal of the National Cancer Institute
- Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
- (2015) T. Dogruluk et al. CANCER RESEARCH
- Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
- (2015) L. M. Draper et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
- (2015) Yassine Lalami et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma
- (2015) Maura L. Gillison et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
- (2015) Juan Madoz-Gúrpide et al. Journal of Translational Medicine
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1 Phosphorylation
- (2015) G. J. Cerniglia et al. MOLECULAR CANCER THERAPEUTICS
- Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
- (2015) B. Gabrielli et al. MOLECULAR CANCER THERAPEUTICS
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2015) Antonio Jimeno et al. ORAL ONCOLOGY
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2014) A. Jimeno et al. ANNALS OF ONCOLOGY
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- Head and Neck Cancer: Global Burden and Regional Trends in India
- (2014) Anupam Mishra et al. Asian Pacific Journal of Cancer Prevention
- High-risk HPV types and head and neck cancer
- (2014) Dominique S. Michaud et al. INTERNATIONAL JOURNAL OF CANCER
- Harnessing Massively Parallel Sequencing in Personalized Head and Neck Oncology
- (2014) M. Jessri et al. JOURNAL OF DENTAL RESEARCH
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
- (2014) T. Mazumdar et al. MOLECULAR CANCER THERAPEUTICS
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Next generation sequencing and its application in deciphering head and neck cancer
- (2014) Maryam Jessri et al. ORAL ONCOLOGY
- Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air Pollution
- (2014) Ian Chi Kei Wong et al. Chinese Journal of Cancer
- Th17 Cells in Cancer: The Ultimate Identity Crisis
- (2014) Stefanie R. Bailey et al. Frontiers in Immunology
- Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models
- (2013) Sarah Elizabeth Wheeler et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
- (2013) David Vasquez-Dunddel et al. JOURNAL OF CLINICAL INVESTIGATION
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
- (2013) Friederike Göke et al. MODERN PATHOLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
- (2013) Stephen B. Keysar et al. Molecular Oncology
- A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
- (2013) Sewanti Limaye et al. ORAL ONCOLOGY
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma†
- (2012) C. Xue et al. ANNALS OF ONCOLOGY
- Lessons learned from next-generation sequencing in head and neck cancer
- (2012) Myriam Loyo et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Enhancement of radiation response with bevacizumab
- (2012) Tien Hoang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
- (2012) Jian Yang et al. STEM CELLS
- Human papillomavirus, smoking, and head and neck cancer
- (2011) Parul Sinha et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
- (2011) Makoto Mitsunaga et al. NATURE MEDICINE
- Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
- (2011) N. Agrawal et al. SCIENCE
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
- (2010) Lydia Durant et al. IMMUNITY
- HPV-associated head and neck cancer: a virus-related cancer epidemic
- (2010) Shanthi Marur et al. LANCET ONCOLOGY
- Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
- (2009) D. Liu et al. CANCER RESEARCH
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
- (2008) Jan. B. Vermorken et al. CANCER
- Gene-environment interaction in tobacco-related cancers
- (2008) E. Taioli CARCINOGENESIS
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
- (2008) Pingyan Cheng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT3: An Important Regulator of Multiple Cytokine Functions
- (2008) Stanislaw M. Stepkowski et al. TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started